DK2968479T3 - Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf - Google Patents
Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf Download PDFInfo
- Publication number
- DK2968479T3 DK2968479T3 DK14775400.6T DK14775400T DK2968479T3 DK 2968479 T3 DK2968479 T3 DK 2968479T3 DK 14775400 T DK14775400 T DK 14775400T DK 2968479 T3 DK2968479 T3 DK 2968479T3
- Authority
- DK
- Denmark
- Prior art keywords
- sure
- therapeutic
- preparing
- methods
- ceramidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784594P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/026481 WO2014160390A1 (en) | 2013-03-14 | 2014-03-13 | Therapeutic acid ceramidase compositions and methods of making and using them |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2968479T3 true DK2968479T3 (da) | 2019-08-12 |
Family
ID=51625420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14775400.6T DK2968479T3 (da) | 2013-03-14 | 2014-03-13 | Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
Country Status (14)
Country | Link |
---|---|
US (3) | US9937246B2 (da) |
EP (2) | EP2968479B1 (da) |
JP (4) | JP6832158B2 (da) |
CA (1) | CA2905449A1 (da) |
DK (1) | DK2968479T3 (da) |
ES (1) | ES2739811T3 (da) |
HK (1) | HK1220399A1 (da) |
HR (1) | HRP20191361T1 (da) |
HU (1) | HUE046113T2 (da) |
IL (4) | IL241390B (da) |
MX (2) | MX2015012471A (da) |
PL (1) | PL2968479T3 (da) |
PT (1) | PT2968479T (da) |
WO (1) | WO2014160390A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
ES2791760T3 (es) | 2011-09-07 | 2020-11-05 | Sinai School Medicine | Ceramidasa y diferenciación celular |
LT2854910T (lt) | 2012-06-01 | 2020-05-25 | Icahn School Of Medicine At Mount Sinai | Ceramido lygiai infekcijos gydymo ir prevencijos metu |
PT2968479T (pt) * | 2013-03-14 | 2019-08-07 | Icahn School Med Mount Sinai | Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização |
AU2018207564A1 (en) * | 2017-01-13 | 2019-08-08 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating farber disease |
RU2020118032A (ru) | 2018-02-02 | 2022-03-02 | Асераген, Инк. | Способы лечения болезни фарбера |
WO2019186272A1 (en) * | 2018-03-27 | 2019-10-03 | Enzyvant Therapeutics Gmbh | Farber disease markers and uses thereof |
US20210244827A1 (en) * | 2018-06-29 | 2021-08-12 | Icahn School Of Medicine At Mount Sinai | Anc80 encoding sphingolipid-metabolizing proteins |
WO2020152532A1 (en) | 2019-01-23 | 2020-07-30 | Enzyvant Therapeutics Gmbh | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH585793A5 (da) | 1974-02-01 | 1977-03-15 | Nestle Sa | |
JPS5322158B2 (da) | 1974-05-02 | 1978-07-06 | ||
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
IT1130242B (it) | 1980-02-01 | 1986-06-11 | Anic Spa | Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0463109A4 (en) | 1989-03-24 | 1992-11-19 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
US5382524A (en) | 1990-10-24 | 1995-01-17 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
US5433946A (en) | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
JPH08505619A (ja) | 1992-12-30 | 1996-06-18 | ジョー レビス,ジョージ | 抗虫歯組成物 |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
CA2163860A1 (en) | 1993-06-30 | 1995-01-12 | Chung C. Hsu | Method for preparing liposomes |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
US7018628B1 (en) | 1998-07-24 | 2006-03-28 | Aventis Pharma S.A. | Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
US6258581B1 (en) | 1998-08-20 | 2001-07-10 | Takara Shuzo Co., Ltd. | Ceramidase gene |
GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
US6730297B1 (en) | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
US6767741B1 (en) | 1999-08-27 | 2004-07-27 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
JP2003516122A (ja) | 1999-10-13 | 2003-05-13 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Dapキナーゼのショートセグメント |
US6350768B1 (en) | 1999-11-24 | 2002-02-26 | Aventis Pharma S.A. | Combination of riluzole and of gabapentin and its use as a medicament |
US7850984B2 (en) | 2000-02-15 | 2010-12-14 | The General Hospital Corporation | Protection of the female reproductive system from natural and artificial insults |
IL152110A0 (en) | 2000-04-06 | 2003-07-31 | Exegenics Inc | Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase) |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
EP1363643A2 (en) | 2000-12-22 | 2003-11-26 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
US20020142299A1 (en) | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
EP1234816B1 (de) | 2001-02-23 | 2004-06-30 | Biofrontera Pharmaceuticals GmbH | Scyphostatin-Analoga als SMase-Inhibitoren |
JP4641705B2 (ja) | 2001-04-30 | 2011-03-02 | ザイストール セラピューティクス, インコーポレイテッド | 治療的タンパク質の亜細胞標的化 |
US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
CA2473360A1 (en) | 2002-01-25 | 2003-08-07 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
AU2003224880A1 (en) | 2002-04-05 | 2003-10-27 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
DE10239531A1 (de) | 2002-08-23 | 2004-03-04 | Gulbins, Erich, Prof. Dr. | Prophylaxe und Therapie von Infektionserkrankungen |
EP1431399A1 (en) | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
ATE521701T1 (de) | 2003-01-22 | 2011-09-15 | Univ Duke | Verbesserte konstrukte zur expression lysosomaler polypeptide |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
CN105316405A (zh) | 2003-07-17 | 2016-02-10 | 环太平洋生物技术有限公司 | 用于胃癌检测的标记物 |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
US7273756B2 (en) | 2004-10-01 | 2007-09-25 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
US8017394B2 (en) | 2004-10-01 | 2011-09-13 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
WO2006050265A2 (en) | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
JP2008537143A (ja) | 2005-04-19 | 2008-09-11 | バーミリオン, インコーポレイテッド | アルツハイマー病のためのバイオマーカーであるサポシンd及びfam3c |
US7981399B2 (en) | 2006-01-09 | 2011-07-19 | Mcgill University | Method to determine state of a cell exchanging metabolites with a fluid medium by analyzing the metabolites in the fluid medium |
CA2640614A1 (en) | 2006-01-27 | 2007-08-09 | Eastern Virginia Medical School | Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential |
WO2007095688A1 (en) | 2006-02-23 | 2007-08-30 | The Australian National University | Methods for increasing the number of circulating cells |
AU2007241622A1 (en) | 2006-04-24 | 2007-11-01 | Academisch Medisch Centrum | Improved treatment of cystic fibrosis |
WO2007136635A1 (en) | 2006-05-16 | 2007-11-29 | Musc Foundation For Research Development | Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators |
US20080057590A1 (en) | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
BRPI0713572A2 (pt) | 2006-06-20 | 2012-10-23 | Stephen Duguay | meios livres de soro e seus usos para expansão de condrócitos |
WO2008086296A2 (en) * | 2007-01-05 | 2008-07-17 | Mount Sinai School Of Medicine | Acid ceramidase and cell survival |
DK2132562T3 (da) | 2007-04-06 | 2012-04-30 | Genzyme Corp | Fremgangsmåder til at vurdere celler og cellekulturer |
AU2008256644B2 (en) | 2007-05-24 | 2014-07-03 | The United States Government As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
DK2164501T3 (da) | 2007-05-31 | 2016-05-30 | Paradigm Biopharmaceuticals Ltd | Sulfaterede xylaner til behandling eller profylakse af luftvejssygdomme |
FR2924946B1 (fr) * | 2007-12-18 | 2010-02-26 | Oreal | Utilisation cosmetique de proteines de type ceramidase acide |
DE102007063535A1 (de) | 2007-12-21 | 2009-06-25 | Cycnad Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose |
EP2659904B1 (en) | 2008-06-26 | 2015-09-16 | Orphazyme APS | Use of Hsp70 as a regulator of enzymatic activity |
US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
JP5721631B2 (ja) | 2008-11-06 | 2015-05-20 | ムスク ファウンデーション フォー リサーチ デベロップメント | 酸性セラミダーゼのリソソーム親和性阻害剤 |
WO2010127355A1 (en) | 2009-05-01 | 2010-11-04 | Mount Sinai School Of Medicine | Method to determine embryo and oocyte quality based on ceramidase |
KR20200034828A (ko) * | 2009-08-28 | 2020-03-31 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
AU2010308397B2 (en) | 2009-10-19 | 2016-04-07 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
US11458119B2 (en) | 2009-11-27 | 2022-10-04 | Genzyme Corporation | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
WO2012051415A2 (en) | 2010-10-13 | 2012-04-19 | Mount Sinai School Of Medicine | Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies |
WO2013101276A2 (en) | 2011-04-01 | 2013-07-04 | Mount Sinai School Of Medicine | Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway |
CA2833907A1 (en) * | 2011-05-10 | 2012-11-15 | Advanced Liquid Logic, Inc. | Enzyme concentration and assays |
WO2012177778A1 (en) | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
ES2791760T3 (es) * | 2011-09-07 | 2020-11-05 | Sinai School Medicine | Ceramidasa y diferenciación celular |
LT2854910T (lt) * | 2012-06-01 | 2020-05-25 | Icahn School Of Medicine At Mount Sinai | Ceramido lygiai infekcijos gydymo ir prevencijos metu |
US9341787B2 (en) | 2013-01-02 | 2016-05-17 | Micron Technology, Inc. | Apparatus providing simplified alignment of optical fiber in photonic integrated circuits |
PT2968479T (pt) * | 2013-03-14 | 2019-08-07 | Icahn School Med Mount Sinai | Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização |
-
2014
- 2014-03-13 PT PT14775400T patent/PT2968479T/pt unknown
- 2014-03-13 WO PCT/US2014/026481 patent/WO2014160390A1/en active Application Filing
- 2014-03-13 DK DK14775400.6T patent/DK2968479T3/da active
- 2014-03-13 ES ES14775400T patent/ES2739811T3/es active Active
- 2014-03-13 PL PL14775400T patent/PL2968479T3/pl unknown
- 2014-03-13 CA CA2905449A patent/CA2905449A1/en active Pending
- 2014-03-13 HU HUE14775400A patent/HUE046113T2/hu unknown
- 2014-03-13 JP JP2016502154A patent/JP6832158B2/ja active Active
- 2014-03-13 EP EP14775400.6A patent/EP2968479B1/en active Active
- 2014-03-13 MX MX2015012471A patent/MX2015012471A/es unknown
- 2014-03-13 EP EP19183045.4A patent/EP3659619A1/en active Pending
- 2014-03-13 US US14/776,442 patent/US9937246B2/en active Active
-
2015
- 2015-09-09 IL IL241390A patent/IL241390B/en active IP Right Grant
- 2015-09-11 MX MX2022003486A patent/MX2022003486A/es unknown
-
2016
- 2016-07-19 HK HK16108585.6A patent/HK1220399A1/zh unknown
-
2018
- 2018-03-01 US US15/909,609 patent/US10238721B2/en active Active
-
2019
- 2019-02-08 US US16/271,433 patent/US10918702B2/en active Active
- 2019-05-08 JP JP2019088262A patent/JP6832386B2/ja active Active
- 2019-07-29 HR HRP20191361 patent/HRP20191361T1/hr unknown
-
2020
- 2020-01-23 IL IL272214A patent/IL272214B/en unknown
- 2020-11-20 JP JP2020193258A patent/JP2021042227A/ja active Pending
-
2021
- 2021-11-25 IL IL288427A patent/IL288427A/en unknown
-
2022
- 2022-11-25 JP JP2022188534A patent/JP2023015402A/ja active Pending
-
2023
- 2023-07-20 IL IL304629A patent/IL304629A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL241390A0 (en) | 2015-11-30 |
WO2014160390A1 (en) | 2014-10-02 |
JP2019150042A (ja) | 2019-09-12 |
PT2968479T (pt) | 2019-08-07 |
US10918702B2 (en) | 2021-02-16 |
US20180193436A1 (en) | 2018-07-12 |
EP3659619A1 (en) | 2020-06-03 |
EP2968479A4 (en) | 2016-07-27 |
IL241390B (en) | 2020-03-31 |
IL272214B (en) | 2022-01-01 |
MX2022003486A (es) | 2022-04-25 |
JP2016520519A (ja) | 2016-07-14 |
CA2905449A1 (en) | 2014-10-02 |
US20160038574A1 (en) | 2016-02-11 |
IL304629A (en) | 2023-09-01 |
HUE046113T2 (hu) | 2020-02-28 |
JP2023015402A (ja) | 2023-01-31 |
ES2739811T3 (es) | 2020-02-04 |
IL288427A (en) | 2022-01-01 |
BR112015024538A2 (pt) | 2018-05-08 |
MX2015012471A (es) | 2016-08-03 |
JP2021042227A (ja) | 2021-03-18 |
JP6832158B2 (ja) | 2021-02-24 |
JP6832386B2 (ja) | 2021-02-24 |
HRP20191361T1 (hr) | 2019-11-01 |
HK1220399A1 (zh) | 2017-05-05 |
EP2968479A1 (en) | 2016-01-20 |
US20190231857A1 (en) | 2019-08-01 |
US9937246B2 (en) | 2018-04-10 |
IL272214A (en) | 2020-03-31 |
US10238721B2 (en) | 2019-03-26 |
EP2968479B1 (en) | 2019-07-17 |
PL2968479T3 (pl) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
DK3019200T3 (da) | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf | |
DK3080274T3 (da) | Fremgangsmåder og sammensætninger til genom-manipulation | |
IL286759A (en) | Therapeutic methods and preparations | |
DK3019483T3 (da) | Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse | |
DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
DK3065771T3 (da) | Fremgangsmåder og sammensætninger til vedvarende immunterapi | |
DK2955996T3 (da) | Kultiveringsbundsystem og fremgangsmåde til dets anvendelse | |
DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
DK2968479T3 (da) | Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf | |
DK3102189T3 (da) | Sammensætning og fremgangsmåde til at fremme søvn | |
DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
DK3025586T3 (da) | Sammensætning til bekæmpelse af plantesygdomme og anvendelse deraf | |
DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
DK3024428T3 (da) | Sammensætninger og fremgangsmåder til dental mineralisering | |
DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf | |
DK3011041T3 (da) | Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter | |
DK3013326T3 (da) | Skaldannende sammensætninger til bløde kapsler og bløde kapsler | |
DK2964374T3 (da) | Synteseanordning og fremgangsmåde | |
DK2896694T3 (da) | Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
DK3022361T4 (da) | Rambuk og fremgangsmåde til anvendelse deraf | |
DK3016547T3 (da) | Dyrebarriere og fremgangsmåde | |
DK3159296T3 (da) | Reb til elevator og fremstillingsfremgangsmåde dertil |